ICICI Direct's research report on Cipla
Q3 revenues grew 18.2% YoY to rS 5169 crore led by strong growth in domestic and RoW markets. Domestic sales grew 25.5% YoY to rS 2231 crore. RoW markets business grew 47.2% YoY to rS 823 whereas South Africa business fell 2.5% YoY to rS 579 crore. US grew 9.6% YoY to rS 1037 crore. EBITDA margins expanded 647 bps YoY to 23.8% mainly due to significantly lower other expenditure. Hence, EBITDA grew 62.3% YoY to rS 1231 crore. PAT more than doubled to rS 748 crore vs. rS 351 crore in Q3FY20
Outlook
We maintain BUY with a target price of rS 975 (vs. earlier rS 965) including base business value of rS 935 (25x FY23E EPS rS 37.4 + rS 42 NPV for gRevlimid.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.